NCT07529535 2026-04-17
A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1 Suspended
Clinical Trials
13 trialsNCT05938296 2025-11-19
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
Binhui Biopharmaceutical Co., Ltd.
Phase 1 Suspended
NCT04381806 2025-10-29
Phase I Study in Advanced Malignancies With 5-ALA
Fox Chase Cancer Center
Phase 1 Suspended
NCT05055518 2025-06-27
APL-102 Capsule in Patients With Advanced Solid Tumors
Apollomics Inc.
Phase 1 Suspended
NCT05571969 2025-05-07
Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Allarity Therapeutics
Phase 1 Suspended
NCT04485416 2025-04-10
CCPO011
University of California, Davis
Phase 1 Suspended
NCT05076591 2024-10-30
IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 1 Suspended
NCT03859752 2023-09-22
TR1801-ADC in Patients With Tumors That Express c-Met
Open Innovation Partners, Inc.
Phase 1 Suspended
NCT01762410 2014-09-29
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Piramal Enterprises Limited
Phase 1 Suspended
NCT01779336 2014-09-29
Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Piramal Enterprises Limited
Phase 1 Suspended
NCT01604863 2012-11-01
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Phase 1 Suspended
NCT00003980 2012-07-11
BIBX 1382 in Treating Patients With Solid Tumors
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Suspended
NCT00591682 2008-03-26
MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Metastatix, Inc.
Phase 1 Suspended